Citations

Clear

17 citation(s) found for "Roy, Bhaskar".

Provisional practice recommendation for the management of myopathy in VCP‐associated multisystem proteinopathy
Roy, Bhaskar , Peck, Allison , Evangelista, Teresinha , Díaz‐Manera, Jordi , Korb, Manisha Kak , Wicklund, Matthew , Milone, Margherita , Freimer, Miriam , Kushlaf, Hani , Villar‐Quiles, Rocío‐Nur , Stojkovic, Tanya , Needham, Merrilee , Palmio, Johanna , Keung, Benison , Mozaffar, Tahseen , Weihl, Conrad C. , Kimonis, Virginia , Milone, M , Díaz-Manera, Jordi , Pfeffer, Gerald , Wang, Leo L. , Lloyd, Thomas E , Roy, Bhaskar

Mayo Clinic

Annals of Clinical and Translational Neurology | April 7, 2023 | Volume: 10 | Issue: 5 | Pages: 686-695

10.1002/acn3.51760 | PMID 37026610 Get It

AbstractValosin‐containing protein (VCP)‐associated multisystem proteinopathy (MSP) is a rare genetic disorder with abnormalities in the autophagy pathway leading to various combinations of myopathy, bone diseases, and neurodegeneration. Ninety percent of patients with VCP‐associated MSP have myopathy, but there is no consensus‐based guideline. The goal of this working group was to develop a best practice set of provisional recommendations for VCP myopathy which can be easily implemented across the globe. As an initiative by Cure VCP Disease Inc., a patient advocacy organization, an online survey was initially conducted to identify the practice gaps in VCP myopathy. All prior published literature on VCP myopathy was reviewed to better understand the different aspects of management of VCP myopathy, and several working group sessions were conducted involving international experts to develop this provisional recommendation. VCP myopathy has a heterogeneous clinical phenotype and should be considered in patients with limb‐girdle muscular dystrophy phenotype, or any myopathy with an autosomal dominant pattern of inheritance. Genetic testing is the only definitive way to diagnose VCP myopathy, and single‐variant testing in the case of a known familial VCP variant, or multi‐gene panel sequencing in undifferentiated cases can be considered. Muscle biopsy is important in cases of diagnostic uncertainty or lack of a definitive pathogenic genetic variant since rimmed vacuoles (present in ~40% cases) are considered a hallmark of VCP myopathy. Electrodiagnostic studies and magnetic resonance imaging can also help rule out disease mimics. Standardized management of VCP myopathy will optimize patient care and help future research initiatives.
Current status of clinical outcome measures in inclusion body myositis: a systematised review
Goyal, Namita , Alfano, Lindsay N. , Garand, Kendrea L. , Mochel, David, Badrising, Umesh A. , Machado, Pedro , Pagkatipunan, Ruben, Funaro, Melissa , Schmidt, Jens , Kushlaf, Hani , Schiopu, Elena , Goyal, Neelam , d’Alessandro, Miriana , Conticini, Edoardo , Cruz-Coble, Betsaida, Machado, Pedro M , Roy, Bhaskar , Lucchini, Matteo , Lilleker, James B , Naddaf, Elie , Adler, Brittany L. , Malandraki, Georgia A. , Wang, Leo L. , Stipancic, Kaila L. , Goyal, Neelam, Lloyd, Thomas E

Mayo Clinic

Clinical and Experimental Rheumatology | February 10, 2023 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.55563/clinexprheumatol/ifacv3 | PMID 36762744 Get It

Targeting LRRC15 Inhibits Metastatic Dissemination of Ovarian Cancer
Ray, Upasana, Jung, Deok-Beom, Jin, Ling, Xiao, Yinan , Dasari, Subramanyam, Bhattacharya, Sayantani Sarkar , Thirusangu, Prabhu, Staub, Julie , Roy, Debarshi, Roy, Bhaskar, Weroha, S. John, Hou, Xiaonan, Purcell, James W., Bakkum-Gamez, Jamie N., Mitra, Anirban K., Shridhar, Viji, Thirusangu, Prabhu , Dasari, Subramanyam , Ray, Upasana , Sarkar Bhattacharya, Sayantani , Staub, Julie K , Kaufmann, Scott H , Kannan, Nagarajan , Ray, Upasana, Jung, Deok-Beom, Jin, Ling, Xiao, Yinan , Thirusangu, Prabhu, Roy, Debarshi, Roy, Bhaskar, Weroha, S. John, Hou, Xiaonan, Purcell, James W., Bakkum-Gamez, Jamie N., Mitra, Anirban K., Shridhar, Viji

Mayo Clinic

Cancer Research | October 15, 2021 | Volume: 82 | Issue: 6 | Pages: 1038-1054

10.1158/0008-5472.can-21-0622 | PMID 34654724 Get It

Abstract Dissemination of ovarian cancer cells can lead to inoperable metastatic lesions in the bowel and omentum that cause patient death. Here we show that LRRC15, a type-I 15-leucine–rich repeat-containing membrane protein, highly overexpressed in ovarian cancer bowel metastases compared with matched primary tumors and acts as a potent promoter of omental metastasis. Complementary models of ovarian cancer demonstrated that LRRC15 expression leads to inhibition of anoikis-induced cell death and promotes adhesion and invasion through matrices that mimic omentum. Mechanistically, LRRC15 interacted with β1-integrin to stimulate activation of focal adhesion kinase (FAK) signaling. As a therapeutic proof of concept, targeting LRRC15 with the specific antibody–drug conjugate ABBV-085 in both early and late metastatic ovarian cancer cell line xenograft models prevented metastatic dissemination, and these results were corroborated in metastatic patient-derived ovarian cancer xenograft models. Furthermore, treatment of 3D-spheroid cultures of LRRC15-positive patient-derived ascites with ABBV-085 reduced cell viability. Overall, these data uncover a role for LRRC15 in promoting ovarian cancer metastasis and suggest a novel and promising therapy to target ovarian cancer metastases. Significance: This study identifies that LRRC15 activates β1-integrin/FAK signaling to promote ovarian cancer metastasis and shows that the LRRC15-targeted antibody–drug conjugate ABBV-085 suppresses ovarian cancer metastasis in preclinical models.
S0390 Expression of PD1 and PDL1 in Dysplastic BE Tissue and Early Esophageal Carcinoma
Ghosh, Prithwish , Linn, Bryan, Mangels-Dick, Tiffany, Hanada, Yuri , Wang, Kenneth K. , Roy, Bhaskar

Mayo Clinic

American Journal of Gastroenterology | October 24, 2020 | Volume: 115 | Issue: 1 | Pages: S193-S194

10.14309/01.ajg.0000703608.52327.eb Get It

SIRT7‐mediated modulation of glutaminase 1 regulates TGF‐β‐induced pulmonary fibrosis
Choudhury, Malay , Yin, Xueqian , Schaefbauer, Kyle, Kang, Jeong Han , Leof, Edward B. , Schaefbauer, Kyle J., Kottom, Theodore J. , Roy, Bhaskar, Limper, Andrew H.

Mayo Clinic

The FASEB Journal | July 27, 2020 | Volume: 34 | Issue: 7 | Pages: 8920-8940

10.1096/fj.202000564r | PMID 32519817 Get It

Abstract In the current work we show that the profibrotic actions of TGF‐β are mediated, at least in part, through a metabolic maladaptation in glutamine metabolism and how the inhibition of glutaminase 1 (GLS1) reverses pulmonary fibrosis. GLS1 was found to be highly expressed in fibrotic vs normal lung fibroblasts and the expression of profibrotic targets, cell migration, and soft agar colony formation stimulated by TGF‐β required GLS1 activity. Moreover, knockdown of SMAD2 or SMAD3 as well as inhibition of PI3K, mTORC2, and PDGFR abrogated the induction of GLS1 by TGF‐β. We further demonstrated that the NAD‐dependent protein deacetylase, SIRT7, and the FOXO4 transcription factor acted as endogenous brakes for GLS1 expression, which are inhibited by TGF‐β. Lastly, administration of the GLS1 inhibitor CB‐839 attenuated bleomycin‐induced pulmonary fibrosis. Our study points to an exciting and unexplored connection between epigenetic and transcriptional processes that regulate glutamine metabolism and fibrotic development in a TGF‐β‐dependent manner.
Verteporfin- and sodium porfimer-mediated photodynamic therapy enhances pancreatic cancer cell death without activating stromal cells in the microenvironment
Lu, Jingjing , Anderson, Marlys , Leggett, Cadman L. , Levy, Michael J. , Hasan, Tayyaba , Wang, Kenneth K. , Hasan, Tayyaba , Leggett, Cadman L , Roy, Bhaskar, Pogue, Brian W.

Mayo Clinic

Journal of Biomedical Optics | November 18, 2019 | Volume: 24 | Issue: 11 | Pages: 1

10.1117/1.jbo.24.11.118001 | PMID 31741351 Get It

Human Fibrinogen for Maintenance and Differentiation of Induced Pluripotent Stem Cells in Two Dimensions and Three Dimensions
Gandhi, Jarel K. , Knudsen, Travis, Hill, Matthew, Bachman, Lori A. , Pfannkoch‐Andrews, Cynthia, Schmidt, Karina N., Metko, Muriel M., Ackerman, Michael J. , Resch, Zachary T., Pulido, José S. , Marmorstein, Alan D. , Bachman, Lori, Pfannkoch-Andrews, Cynthia, Resch, Zachary, Roy, Bhaskar , Marmorstein, Alan D

Mayo Clinic

Stem Cells Translational Medicine | February 15, 2019 | Volume: 8 | Issue: 6 | Pages: 512-521

10.1002/sctm.18-0189 | PMID 30768863 Get It

Abstract Human fibrin hydrogels are a popular choice for use as a biomaterial within tissue engineered constructs because they are biocompatible, nonxenogenic, autologous use compatible, and biodegradable. We have recently demonstrated the ability to culture induced pluripotent stem cell (iPSC)-derived retinal pigment epithelium on fibrin hydrogels. However, iPSCs themselves have relatively few substrate options (e.g., laminin) for expansion in adherent cell culture for use in cell therapy. To address this, we investigated the potential of culturing iPSCs on fibrin hydrogels for three-dimensional applications and further examined the use of fibrinogen, the soluble precursor protein, as a coating substrate for traditional adherent cell culture. iPSCs successfully adhered to and proliferated on fibrin hydrogels. The two-dimensional culture with fibrinogen allows for immediate adaption of culture models to a nonxenogeneic model. Similarly, multiple commercially available iPSC lines adhered to and proliferated on fibrinogen coated surfaces. iPSCs cultured on fibrinogen expressed similar levels of the pluripotent stem cell markers SSea4 (98.7% ± 1.8%), Oct3/4 (97.3% ± 3.8%), TRA1-60 (92.2% ± 5.3%), and NANOG (96.0% ± 3.9%) compared with iPSCs on Geltrex. Using a trilineage differentiation assay, we found no difference in the ability of iPSCs grown on fibrinogen or Geltrex to differentiate to endoderm, mesoderm, or ectoderm. Finally, we demonstrated the ability to differentiate iPSCs to endothelial cells using only fibrinogen coated plates. On the basis of these data, we conclude that human fibrinogen provides a readily available and inexpensive alternative to laminin-based products for the growth, expansion, and differentiation of iPSCs for use in research and clinical cell therapy applications. Stem Cells Translational Medicine 2019;8:512–521